We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma.
- Authors
Eun Kyung Paik; Mi-Sook Kim; Won Il Jang; Young Seok Seo; Chul-Koo Cho; Hyung Jun Yoo; Chul Ju Han; Su Cheol Park; Sang Bum Kim; Young Han Kim; Paik, Eun Kyung; Kim, Mi-Sook; Jang, Won Il; Seo, Young Seok; Cho, Chul-Koo; Yoo, Hyung Jun; Han, Chul Ju; Park, Su Cheol; Kim, Sang Bum; Kim, Young Han
- Abstract
<bold>Background: </bold>This study aimed to evaluate the effect of stereotactic ablative radiotherapy (SABR) after incomplete transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients.<bold>Methods: </bold>The study enrolled 178 HCC patients initially treated with TACE between 2006 and 2011. Patients were included if they had Barcelona Clinic Liver Cancer stage 0 or A, ≤3 nodules with a total sum of longest diameter ≤10 cm, Child-Turcotte-Pugh score of ≤7, no major vessel invasion, and no extra-hepatic metastases.<bold>Results: </bold>Twenty-four patients achieved a complete response to TACE (group 1). Among those with incomplete response, 47 patients received other curative treatments (group 2), 37 received SABR (group 3), and 70 received non-curative treatments (group 4). The 2-year overall survival (OS) rates for groups 1, 2, 3, and 4 were 88 %, 81 %, 73 %, and 54 %, respectively. The corresponding 5-year OS rates were 50 %, 58 %, 53 %, and 28 %, respectively.<bold>Conclusions: </bold>Patients treated with SABR after incomplete TACE had similar survival outcomes to those achieving complete response to TACE or receiving curative treatments. However, patients receiving non-curative treatments had significantly lower survival rates than the other groups. Therefore, if SABR was indicated at the initial diagnosis, it might be recommended after TACE failure.
- Subjects
LIVER cancer; RADIOTHERAPY; STEREOTACTIC radiosurgery; CHEMOEMBOLIZATION; CANCER chemotherapy; ARTERIES; COMBINED modality therapy; DOXORUBICIN; HEPATOCELLULAR carcinoma; LIVER tumors; RADIOSURGERY; SURVIVAL; VEGETABLE oils; TREATMENT effectiveness; RETROSPECTIVE studies
- Publication
Radiation Oncology, 2016, Vol 11, p11
- ISSN
1748-717X
- Publication type
journal article
- DOI
10.1186/s13014-016-0597-7